SPINK1 expression is tightly linked to 6q15- and 5q21-deleted ERG-fusion negative prostate cancers but unrelated to PSA recurrence

Prostate

Volumn 73, Issue 15, 2013, Pages 1690-1698

  Grupp, Katharina ^a   Diebel, Franz ^a   Sirma, Hüseyin ^a   Simon, Ronald ^a   Breitmeyer, Karin ^a   Steurer, Stefan ^a   Hube Magg, Claudia ^a   Prien, Kristina ^a   Pham, Taher ^a   Weigand, Philipp ^a   Michl, Uwe ^a   Heinzer, Hans ^a   Kluth, Martina ^a   Minner, Sarah ^a   Tsourlakis, Maria Christina ^a   Izbicki, Jakob R ^a   Sauter, Guido ^a   Schlomm, Thorsten ^a   Wilczak, Waldemar ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

prostate cancer; SPINK1; tissue microarray

Indexed keywords

APROTININ; BIOLOGICAL MARKER; SERINE PROTEINASE INHIBITOR KAZAL TYPE 1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER TISSUE; CHROMOSOME DELETION; CHROMOSOME DELETION 3P13; CHROMOSOME DELETION 5Q21; CHROMOSOME DELETION 6Q15; COMPARATIVE STUDY; ERG FUSION NEGATIVE PROSTATE CANCER; FOLLOW UP; GENE DELETION; GENE FUSION; GENE REARRANGEMENT; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TISSUE MICROARRAY;

PROSTATE CANCER; SPINK1; TISSUE MICROARRAY;

ADULT; AGED; AGED, 80 AND OVER; CARRIER PROTEINS; CHROMOSOMES, HUMAN, PAIR 5; CHROMOSOMES, HUMAN, PAIR 6; GENE DELETION; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TISSUE ARRAY ANALYSIS; TRANS-ACTIVATORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84884902793     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22707     Document Type: Article

References (36)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D,. Global cancer statistics. CA Cancer J Clin 2011; 61 (2): 69-90.
2. Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, Sboner A, Esgueva R, Pflueger D, Sougnez C, Onofrio R, Carter SL, Park K, Habegger L, Ambrogio L, Fennell T, Parkin M, Saksena G, Voet D, Ramos AH, Pugh TJ, Wilkinson J, Fisher S, Winckler W, Mahan S, Ardlie K, Baldwin J, Simons JW, Kitabayashi N, MacDonald TY, Kantoff PW, Chin L, Gabriel SB, Gerstein MB, Golub TR, Meyerson M, Tewari A, Lander ES, Getz G, Rubin MA, Garraway LA,. The genomic complexity of primary human prostate cancer. Nature 2011; 470 (7333): 214-220.
3. Kazal LA, Spicer DS, Brahinsky RA,. Isolation of a crystalline trypsin inhibitor-anticoagulant protein from pancreas. J Am Chem Soc 1948; 70 (9): 3034-3040.
4. Lamontagne J, Pinkerton M, Block TM, Lu XY,. Hepatitis B and Hepatitis C virus replication upregulates serine protease inhibitor kazal, resulting in cellular resistance to serine protease-dependent apoptosis. J Virol 2010; 84 (2): 907-917.
5. Soon WW, Miller LD, Black MA, Dalmasso C, Chan XB, Pang B, Ong CW, Salto-Tellez M, Desai KV, Liu ET,. Combined genomic and phenotype screening reveals secretory factor SPINK1 as an invasion and survival factor associated with patient prognosis in breast cancer. Embo Mol Med 2011; 3 (8): 451-464.
6. Higashiyama M, Monden T, Tomita N, Murotani M, Kawasaki Y, Morimoto H, Murata A, Shimano T, Ogawa M, Mori T,. Expression of pancreatic secretory trypsin-inhibitor (Psti) in Colorectal-cancer. Br J Cancer 1990; 62 (6): 954-958.
7. Lee YC, Pan HW, Peng SY, Lai PL, Kuo WS, Ou YH, Hsu HC,. Overexpression of tumour-associated trypsin inhibitor (TATI) enhances tumour growth and is associated with portal vein invasion, early recurrence and a stage-independent prognostic factor of hepatocellular carcinoma. Eur J Cancer 2007; 43 (4): 736-744.
8. Tomlins SA, Rhodes DR, Yu JJ, Varambally S, Mehra R, Perner S, Demichelis F, Helgeson BE, Laxman B, Morris DS, Cao Q, Cao XH, Andren O, Fall K, Johnson L, Wei JT, Shah RB, Al-Ahmadie H, Eastham JA, Eggener SE, Fine SW, Hotakainen K, Stenman UH, Tsodikov A, Gerald WL, Lilja H, Reuter VE, Kantoff PW, Scardino PT, Rubin MA, Bjartell AS, Chinnaiyan AM,. The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell 2008; 13 (6): 519-528.
9. Ateeq B, Tomlins SA, Laxman B, Asangani IA, Cao Q, Cao X, Li Y, Wang X, Feng FY, Pienta KJ, Varambally S, Chinnaiyan AM,. Therapeutic targeting of SPINK1-positive prostate cancer. Sci Trans Med 2011; 3 (72): 72ra17.
10. Goldstein AS, Zong Y, Witte ON,. A two-step toward personalized therapies for prostate cancer. Sci Trans Med 2011; 3 (72): 72ps77.
11. Leinonen KA, Tolonen TT, Bracken H, Stenman UH, Tammela TLJ, Saramaki OR, Visakorpi T,. Association of SPINK1 expression and TMPRSS2: ERG fusion with prognosis in endocrine-treated prostate cancer. Clin Cancer Res 2010; 16 (10): 2845-2851.
12. Han B, Mehra R, Suleman K, Tomlins SA, Wang L, Singhal N, Linetzky KA, Palanisamy N, Zhou M, Chinnaiyan AM, Shah RB,. Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma. Mod Pathol 2009; 22 (9): 1176-1185.
13. Bismar TA, Yoshimoto M, Duan QL, Liu SH, Sircar K, Squire JA,. Interactions and relationships of PTEN, ERG, SPINK1 and AR in castration-resistant prostate cancer. Histopathology 2012; 60 (4): 645-652.
14. Paju A, Hotakainen K, Cao Y, Laurila T, Gadaleanu V, Hemminki A, Stenman UH, Bjartell A,. Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells. Eur Urol 2007; 52 (6): 1670-1681.
15. Erbersdobler A, Fritz H, Schnoger S, Graefen M, Hammerer P, Huland H, Henke RP,. Tumour grade, proliferation, apoptosis, microvessel density, p53, and bcl-2 in prostate cancers: Differences between tumours located in the transition zone and in the peripheral zone. Eur Urol 2002; 41 (1): 40-46.
16. Mirlacher M, Simon R,. Recipient block TMA technique. Methods Mol Biol 2010; 664: 37-44.
17. Minner S, Enodien M, Sirma H, Luebke AM, Krohn A, Mayer PS, Simon R, Tennstedt P, Muller J, Scholz L, Brase JC, Liu AY, Schluter H, Pantel K, Schumacher U, Bokemeyer C, Steuber T, Graefen M, Sauter G, Schlomm T,. ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clin Cancer Res 2011; 17 (18): 5878-5888.
18. Burkhardt L, Fuchs S, Krohn A, Masser S, Mader M, Kluth M, Bachmann F, Huland H, Steuber T, Graefen M, Schlomm T, Minner S, Sauter G, Sirma H, Simon R,. CHD1 Is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer. Cancer Res 2013; 73 (9): 2795-2805.
19. Kluth M, Hesse J, Heinl A, Krohn A, Steurer S, Sirma H, Simon R, Mayer PS, Schumacher U, Grupp K, Izbicki JR, Pantel K, Dikomey E, Korbel JO, Plass C, Sauter G, Schlomm T, Minner S,. Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2: ERG fusions. Mod Pathol 2013; 26 (7): 975-983.
20. Krohn A, Diedler T, Burkhardt L, Mayer PS, De Silva C, Meyer-Kornblum M, Kotschau D, Tennstedt P, Huang J, Gerhauser C, Mader M, Kurtz S, Sirma H, Saad F, Steuber T, Graefen M, Plass C, Sauter G, Simon R, Minner S, Schlomm T,. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. Am J Pathol 2012; 181 (2): 401-412.
21. Minner S, Wittmer C, Graefen M, Salomon G, Steuber T, Haese A, Huland H, Bokemeyer C, Yekebas E, Dierlamm J, Balabanov S, Kilic E, Wilczak W, Simon R, Sauter G, Schlomm T,. High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer. Prostate 2011; 71 (3): 281-288.
22. Grupp K, Kohl S, Sirma H, Simon R, Steurer S, Becker A, Adam M, Izbicki J, Sauter G, Minner S, Schlomm T, Tsourlakis MC,. Cysteine-rich secretory protein 3 overexpression is linked to a subset of PTEN-deleted ERG fusion-positive prostate cancers with early biochemical recurrence. Mod Pathol 2013; 26 (5): 733-742.
23. Minner S, Kraetzig F, Tachezy M, Kilic E, Graefen M, Wilczak W, Bokemeyer C, Huland H, Sauter G, Schlomm T,. Low activated leukocyte cell adhesion molecule expression is associated with advanced tumor stage and early prostate-specific antigen relapse in prostate cancer. Human Pathol 2011; 42 (12): 1946-1952.
24. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N, Landers T, Dolgalev I, Major JE, Wilson M, Socci ND, Lash AE, Heguy A, Eastham JA, Scher HI, Reuter VE, Scardino PT, Sander C, Sawyers CL, Gerald WL,. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010; 18 (1): 11-22.
25. Lapointe J, Li C, Giacomini CP, Salari K, Huang S, Wang P, Ferrari M, Hernandez-Boussard T, Brooks JD, Pollack JR,. Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. Cancer Res 2007; 67 (18): 8504-8510.
26. Glinsky GV, Glinskii AB, Stephenson AJ, Hoffman RM, Gerald WL,. Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest 2004; 113 (6): 913-923.
27. Schlomm T, Iwers L, Kirstein P, Jessen B, Kollermann J, Minner S, Passow-Drolet A, Mirlacher M, Milde-Langosch K, Graefen M, Haese A, Steuber T, Simon R, Huland H, Sauter G, Erbersdobler A,. Clinical significance of p53 alterations in surgically treated prostate cancers. Mod Pathol 2008; 21 (11): 1371-1378.
28. Bubendorf L, Sauter G, Moch H, Schmid HP, Gasser TC, Jordan P, Mihatsch MJ,. Ki67 labelling index: An independent predictor of progression in prostate cancer treated by radical prostatectomy. J Pathol 1996; 178 (4): 437-441.
29. Fleischmann A, Schlomm T, Huland H, Kollermann J, Simon P, Mirlacher M, Salomon G, Chun FH, Steuber T, Simon R, Sauter G, Graefen M, Erbersdobler A,. Distinct subcellular expression patterns of neutral endopeptidase (CD10) in prostate cancer predict diverging clinical courses in surgically treated patients. Clin Cancer Res 2008; 14 (23): 7838-7842.
30. Muller J, Ehlers A, Burkhardt L, Sirma H, Steuber T, Graefen M, Sauter G, Minner S, Simon R, Schlomm T, Michl U,. Loss of pSer2448-mTOR expression is linked to adverse prognosis and tumor progression in ERG-fusion-positive cancers. Int J Cancer 2013; 132 (6): 1333-1340.
31. Bjartell A, Paju A, Zhang WM, Gadaleanu V, Hansson J, Landberg G, Stenman UH,. Expression of tumor-associated trypsinogens (TAT-1 and TAT-2) in prostate cancer. Prostate 2005; 64 (1): 29-39.
32. Greene LJ, Pubols MH, Bartelt DC,. Human pancreatic secretory trypsin inhibitor. Methods Enzymol 1976; 45: 813-825.
33. Haverback BJ, Dyce B, Bundy H, Edmondson HA,. Trypsin, trypsinogen and trypsin inhibitor in human pancreatic juice. Am J Med 1960; 29: 421-433.
34. Paju A, Stenman UH,. Biochemistry and clinical role of trypsinogens and pancreatic secretory trypsin inhibitor. Crit Rev Clin Lab Sci 2006; 43 (2): 103-142.
35. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM,. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310 (5748): 644-648.
36. Tomlins SA, Mehra R, Rhodes DR, Cao X, Wang L, Dhanasekaran SM, Kalyana-Sundaram S, Wei JT, Rubin MA, Pienta KJ, Shah RB, Chinnaiyan AM,. Integrative molecular concept modeling of prostate cancer progression. Nat Genet 2007; 39 (1): 41-51.